Clinical trials: Adult Patients
Crohn's Disease
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world.
- Trial name
- NCT06023030
- Where
- 104 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1b Study of PUR1800 in Patients With COPD
This is a randomised, placebo-controlled, double-blind 3-way crossover study in which PUR1800, or placebo is dosed daily for 14 consecutive days in adult subjects with stable COPD over three discrete TPs.
- Trial name
- NCT04759807
- Testing
- PUR1800 250 ug, PUR1800 500 ug
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Pulmatrix Inc.
Asthma Exacerbation, COPD Exacerbation
A Study Evaluating the Use of ResAppDx v2.0 as an Aid to Diagnose Respiratory Disease in Adolescent and Adult Patients in an Emergency Department
Aim is to to demonstrate that the ResAppDx v2.0 algorithms provide an accurate diagnosis of respiratory disease in the study's clinical setting compared to a clinical adjudication committee's (CAC) diagnosis; and to establish a…
- Conditions
- Asthma Exacerbation, COPD Exacerbation, Lower Respiratory Disease, Pneumonia
- Trial name
- NCT06156462
- Testing
- ResAppDx v.20
- Where
- 3 sites in United Kingdom
- Volunteers
- 171 people
- Sponsor
- ResApp Health Limited
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab)…
- Trial name
- NCT01708161
- Testing
- BYL719, AMG 479
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
The purpose of this study is to assess the safety and tolerability of intravenous (IV) carbamazepine (CBZ) administered as multiple 15 minute infusions and a single 5 minute infusion to adult patients with epilepsy on stable…
- Trial name
- NCT01128959
- Testing
- Intravenous Carbamazepine (IV CBZ)
- Where
- 29 sites in United States
- Volunteers
- 108 people
- Sponsor
- Lundbeck LLC
Psoriasis
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712705
- Testing
- HPP737
- Where
- 50 sites in China
- Volunteers
- 515 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Prediabetes
Prospective Observational Study Assessing Treatment and Outcomes of Patients With Prediabetes
The purpose of this observational study is to assess the treatment and outcomes of patients with prediabetes in community-based clinical practices.
- Trial name
- NCT01869101
- Volunteers
- 560 people
- Sponsor
- Tethys Bioscience, Inc.
Onychomycosis
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)
The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.
- Trial name
- NCT00679601
- Testing
- AN2690
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pfizer
Atopic Dermatitis
Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis
The purpose of this study is to identify how pimecrolimus cream 1% modifies the molecular and cellular changes associated with the post-lesional phase of atopic dermatitis (AD).
- Trial name
- NCT00117377
- Testing
- Pimecrolimus
- Where
- 3 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus
This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus.
- Trial name
- NCT00694057
- Testing
- HE3286
- Where
- 22 sites in United States
- Volunteers
- 164 people
- Sponsor
- Harbor Therapeutics
Solid Tumors, Lymphomas
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
The purpose of this trial is to explore the clinical utility of two investigational antibodies in patients with advanced cancer or lymphomas. This is a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT02740270
- Testing
- GWN323, PDR001
- Where
- 9 sites in United States, Canada and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive (COPD)
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
- Trial name
- NCT07039669
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 594 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Renal Insufficiency, Chronic
Bringing Knowledge About Chronic Kidney Disease in Brazil: Filling the Gap
This is a multicenter cross-sectional study will randomly screen kidney function in adult patients with known risk factors for chronic kidney disease (CKD) within the Brazilian general population.
- Trial name
- Filling gap (NCT07103629)
- Where
- Brazil
- Volunteers
- 8,428 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
This is an open-label, multicenter, phase 1 study of BBI608 in combination with Sorafenib. This study population is adult Japanese patients with advanced hepatocellular carcinoma in Sorafenib combination therapy.
- Trial name
- NCT02358395
- Testing
- BBI608, Sorafenib
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
COVID-19
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.
- Trial name
- NCT04410354
- Testing
- Merimepodib, Remdesivir
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- ViralClear Pharmaceuticals, Inc.
Non-Small-Cell Lung Cancer
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
- Trial name
- NCT04681131
- Testing
- CAB-AXL-ADC, PD-1 inhibitor
- Where
- 60 sites in United States, Greece and 5 more
- Volunteers
- 85 people
- Sponsor
- BioAtla, Inc.
Blood Loss
Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Patients During a Blood Draw
Non-invasive monitoring to measure changes in blood volume.
- Trial name
- NCT01846195
- Testing
- CM 1500
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zynex Monitoring Solutions
Respiratory Syncytial Virus Infections
Anti-RSV Study in Chinese Patients (ASCENT)
This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered AK0529 in Chinese adults with RSV infection.
- Trial name
- ASCENT (NCT03699202)
- Testing
- AK0529
- Where
- 22 sites in China
- Volunteers
- 1 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis
An Intermediate Size Expanded Access Protocol of AMX0035 for ALS
The Expanded Access Program will provide access and assess the safety of AMX0035 for the treatment of people living with ALS.
- Trial name
- NCT05286372
- Testing
- AMX0035
- Where
- 21 sites in United States, Puerto Rico
- Sponsor
- Amylyx Pharmaceuticals Inc.
Post-Traumatic Stress Disorder
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
This study is open to people aged 18 to 65 who have post-traumatic stress disorder. The purpose of this study is to find out whether a medicine called BI 1358894 improves symptoms in people with post-traumatic stress disorder.
- Trial name
- NCT05103657
- Testing
- BI 1358894
- Where
- 61 sites in United States, Croatia and 6 more
- Volunteers
- 318 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.